Poster #37

PHASE I MAXIMAL USE PHARMACOKINETIC STUDY OF TIRBANIBULIN OINTMENT 1% IN SUBJECTS WITH ACTINIC KERATOSIS

Regina Yavel,[1] J. Scott Overcash,[2] Jay Zhi,[3] David Cutler,[3] Jane Fang,[3]

[1]TKL Research Inc., Fair Lawn, NJ, USA; [2]eStudySite, La Mesa, CA, USA; [3]Athenex Inc., Buffalo, NY, USA

BACKGROUND

- Tirbanibulin (KX2-391) is a synthetic, highly selective, novel inhibitor of tubulin polymerisation and Src kinase signalling developed as a first-in-class topical formulation for the treatment of actinic keratosis (AK)[1]
- In Phase I/II studies, tirbanibulin was minimally absorbed and systemic exposure was low when applied topically
- Previous Phase I and II studies showed that tirbanibulin ointment 1% for 5 days was effective against AK lesions on the forearm, face and scalp. Local skin reactions (LSRs) were mostly transient and mild-to-moderate in severity, and tirbanibulin was well tolerated.[2,3] These studies supported the further development of the 5-day clinical regimen of tirbanibulin ointment 1% in treating AK on the face/scalp
- Results from two Phase III studies (KX01-AK-003/KX01-AK-004), demonstrated that tirbanibulin ointment 1% self-administered once-daily for 5 days resulted in higher rates of complete lesion clearance at Day 57 compared with placebo (KX01-AK-003: 44% vs. 5%, P<0.0001; KX01-AK-004: 54% vs. 13%, P<0.0001) and was well tolerated, potentially making it a valuable new addition to AK treatment[4] (**See EADO 2020 Poster #35**)
- Here, we present results from a Phase I, open-label, uncontrolled, non-randomised, maximal use pharmacokinetic (PK) study (KX01-AK-007) evaluating the systemic exposure and safety of tirbanibulin ointment 1% (5 days) applied to the face/balding scalp of adults with AK

OBJECTIVES

- The primary objective was to determine the PK of tirbanibulin ointment 1% under maximal use conditions
- Secondary objectives were to evaluate the safety and tolerability of tirbanibulin ointment 1% and to determine the PK of tirbanibulin metabolites

METHODS

Study design

- Subjects (aged ≥18 years) with ≥6 clinically typical, visible and discrete AK lesions on 25 cm^2 of the face/balding scalp were enrolled in the study
- Subjects self-applied sufficient tirbanibulin to cover the treatment area (25 cm^2 area of the face/balding scalp) from the 250 mg sachet once-daily for 5 consecutive days. Subjects were instructed to avoid touching or wetting the treatment area for at least 12 hours after drug application

Study evaluations

Pharmacokinetics

- PK blood sampling (for tirbanibulin and its inactive metabolites [KX2-5036 and KX2-5163]) occurred on Days 1, 3 and 4 at 0 (pre-dose) and on Day 5 at 0, 2, 4, 6, 8, 10, 12, 16 and 24 hours post-the Day 5 application

Safety

- Adverse events (AEs) were assessed
- LSRs (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, erosion/ulceration; scale of 0–3 [absent–severe]) were evaluated on Days 1, 6, 8, 15 and 29; and LSR composite scores were calculated as the sum of all individual LSR scores at each visit with the possible range of 0–18

RESULTS

Baseline characteristics

- In total, 18 subjects (face, n=9; scalp, n=9) were enrolled and completed the study (**Table 1**)
- The mean (standard deviation [SD]) age of subjects was 66.4 (9.42 [range: 43–83]) years
- Subjects were White, predominantly male (83.3%) with Fitzpatrick skin type I–III (94.4%) and a mean (SD) Baseline AK lesion count of 8.2 (2.43 [range: 6–14])
- Mean (SD) dose applied was 137 (44.9) mg among the combined subject group (~55% of the full dose possible, 250 mg)

Table 1. Subject Demographics and Baseline Characteristics

	Face (n=9)	Scalp (n=9)	Combined (N=18)
Mean (SD) age, years	71.1 (6.92)	61.8 (9.58)	66.4 (9.42)
Gender, n (%)			
Female	3 (33.3)	0	3 (16.7)
Male	6 (66.7)	9 (100)	15 (83.3)
Race, n (%)			
White	9 (100)	9 (100)	18 (100)
Ethnicity, n (%)			
Hispanic or Latino	0	2 (22.2)	2 (11.1)
Not Hispanic or Latino	9 (100)	7 (77.8)	16 (88.9)
Fitzpatrick Skin Type,[a] n (%)			
I	2 (22.2)	2 (22.2)	4 (22.2)
II	2 (22.2)	2 (22.2)	4 (22.2)
III	5 (55.6)	4 (44.4)	9 (50.0)
IV	0	1 (11.1)	1 (5.6)
Mean (SD) baseline AK lesion count	8.4 (2.46)	7.9 (2.52)	8.2 (2.43)

[a]Type I: always burns easily, never tans; Type II: always burns easily, tans minimally; Type III: burns moderately, tans gradually; Type IV: burns minimally, always tans well
AK, actinic keratosis; SD, standard deviation

Pharmacokinetics

Tirbanibulin

- Using an LC-MS/MS bioanalytical assay (lower limit of quantification [LLOQ] of 0.01 ng/mL), all subjects had measurable but low concentrations of tirbanibulin at troughs (**Figure 1**)
  - By the observed C_{trough} plateau, the pre-dose concentration C_{trough} data demonstrated that steady-state was achieved following the third dose (72 hours) of once-daily, 5 days of dosing
- On Day 5, mean (SD) C_{max} was 0.258 (0.231) ng/mL (0.598 nM), median t_{max} was 6.91 h, and mean (SD) AUC_{0-24h} was 4.09 (3.15) ng·h/mL (**Table 2**)

Tirbanibulin metabolites

- For the majority of subjects, plasma concentrations for the main tirbanibulin metabolites KX2-5036 (n=14/18) and KX2-5163 (n=13/18) were below the LLOQ of 0.05 ng/mL

Figure 1. (A) Mean Trough Plasma Concentrations of Tirbanibulin at Days 1, 3, 4 and 5; (B) Individual Plasma Concentrations of Tirbanibulin with Overall Mean on Day 5 Post-Dose



Table 2. Tirbanibulin Plasma PK Parameters Following 5 days of Consecutive Topical Dosing

	Face (n=9)	Scalp (n=9)	Combined (N=18)
Mean (SD)			
C_{max} (ng/mL)	0.340 (0.297)	0.176 (0.102)	0.258 (0.231)
t_{max}[a] (h)	6.0 (2.0, 9.8)	7.8 (2.0, 10.0)	6.91 (2.0, 10.0)
AUC_{0-24} (h*ng/mL)	5.0 (3.9)	3.18 (1.92)	4.09 (3.15)

[a]For t_{max}, median (min, max) are reported
AUC_{0-24}, area under the curve from 0-24 hours; C_{max}, maximum plasma concentration; PK, pharmacokinetic; t_{max}, time of maximum concentration

Safety

Adverse events

- Four subjects (face, n=1; scalp, n=3) experienced a total of 5 treatment-emergent AEs (TEAEs); all were unrelated to treatment
- One subject in the scalp-treated group experienced a treatment-related TEAE (mild skin dryness; resolved spontaneously)
- There were no serious AEs, severe AEs, deaths or TEAEs leading to study discontinuation

Local skin reactions

- LSRs on the treatment area were mostly transient, all were mild-to-moderate erythema and flaking/scaling that peaked around Day 8 (mean [SD] composite score: 3.4 [1.76]) before resolving or returning to baseline

CONCLUSIONS

- Under maximal use conditions, low systemic exposure of tirbanibulin with subnanomolar plasma concentrations for both parent drug and metabolites was confirmed
- Overall, tirbanibulin ointment 1% for 5 days was well tolerated for the treatment of AK on the face/balding scalp

REFERENCES

1. Smolinksi MP, et al. J Med Chem. 2018;61:4707-4719
2. DuBois J, et al. Phase I study of tirbanibulin ointment 1%, a novel Src phosphorylation and tubulin polymerization inhibitor, in subjects with actinic keratosis. Poster presented at the 6th Annual Practical Symposium, Beaver Creek, CO, USA, August 8–11, 2019
3. DuBois J, et al. Phase II study of tirbanibulin ointment 1%, a novel Src phosphorylation and tubulin polymerization inhibitor, for actinic keratosis. Poster presented at the 6th Annual Practical Symposium, Beaver Creek, CO, USA, August 8–11, 2019
4. Blauvelt A, et al. Tirbanibulin ointment 1% for actinic keratosis (AK): Results from two Phase 3 studies with 1-year follow-up. Poster presented at the Maui Derm Virtual Congress, June 24–27, 2020

DISCLOSURES

This study was sponsored by Athenex, Inc.

ACKNOWLEDGEMENTS

Editorial support, under the direction of the authors, was provided by Emma Mitchell, PhD, on behalf of CMC AFFINITY, McCann Health Medical Communications in accordance with Good Publication Practice (GPP3) guidelines and was funded by Almirall, SA.